Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y, Bueno D, Sisinni L, Fernández-Arroyo A, Rosich B, Martínez AP, Benítez-Carabante MI, Alonso L, Uría ML, Heredia CD, Mestre-Duran C, Pascual CFB, Torres J, Losantos I, Escudero A, Ruz-Caracuel B.
Mozo Y, et al. Among authors: fernandez arroyo a.
Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4.
Pediatr Hematol Oncol. 2021.
PMID: 33661711